Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor Moreno

Showing results (331-340 of 548) with videos related to

Pageof 55
Sort By:
Molecular Cancer Therapeutics|June 20, 2017
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
Carcinogenesis|January 12, 2012
Susceptibility genetic variants associated with early-onset colorectal cancerMaría Dolores Giráldez, Adriana López-Dóriga, Luis Bujanda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration StudyVictor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic MalignanciesJason J Luke, Karen Gelmon, Lillian L Siu, et al.
The Lancet. Oncology|July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialShahneen K Sandhu, William R Schelman, George Wilding, et al.
Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Healthcare (Basel, Switzerland)|October 16, 2024
Health-Related Quality of Life in Long-Term Colorectal Cancer SurvivorsAlba Marcos-Delgado, Vicente Martín-Sánchez, Ana Molina-Barceló, et al.
Journal of Clinical Medicine|April 27, 2024
Exploring the Associations of Inflammatory and Oxidative Stress Biomarkers with Pancreatic Diseases: An Observational and Mendelian Randomisation StudyLaura Vilà-Quintana, Esther Fort, Laura Pardo, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pathway Polygenic Risk Scores (pPRS) for the Analysis of Gene-environment InteractionW James Gauderman, Yubo Fu, Bryan Queme, et al.
Pageof 55

Showing results (331-340 of 548) with videos related to

Sort By:
Pageof 55
Molecular Cancer Therapeutics|June 20, 2017
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
Carcinogenesis|January 12, 2012
Susceptibility genetic variants associated with early-onset colorectal cancerMaría Dolores Giráldez, Adriana López-Dóriga, Luis Bujanda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 26, 2014
Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration StudyVictor Moreno García, David Olmos, Carlos Gomez-Roca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic MalignanciesJason J Luke, Karen Gelmon, Lillian L Siu, et al.
The Lancet. Oncology|July 2, 2013
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trialShahneen K Sandhu, William R Schelman, George Wilding, et al.
Journal for Immunotherapy of Cancer|October 13, 2020
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumorsAlbiruni Ra Razak, James M Cleary, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Healthcare (Basel, Switzerland)|October 16, 2024
Health-Related Quality of Life in Long-Term Colorectal Cancer SurvivorsAlba Marcos-Delgado, Vicente Martín-Sánchez, Ana Molina-Barceló, et al.
Journal of Clinical Medicine|April 27, 2024
Exploring the Associations of Inflammatory and Oxidative Stress Biomarkers with Pancreatic Diseases: An Observational and Mendelian Randomisation StudyLaura Vilà-Quintana, Esther Fort, Laura Pardo, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Pathway Polygenic Risk Scores (pPRS) for the Analysis of Gene-environment InteractionW James Gauderman, Yubo Fu, Bryan Queme, et al.
Pageof 55